Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials

Current Opinion in Cardiology

Volumn 17, Issue 1, 2002, Pages 6-18

  Naccarella, Franco ^a   Naccarelli, Gerald V ^a   Sdringola Maranga, Stefano ^a   Lepera, Giovannina ^a   Grippo, Maria Carmela ^a   Melandri, Francesco ^a   Gatti, Mauro ^a   Pazzaglia, Stefano ^a   Spinelli, Giovanna ^a   Angelini, Vittorio ^a   Ambrosioni, Ettore ^a   Borghi, Claudio ^a   Giovagnorio, Maria Teresa ^a   Nisam, Seah ^a  

^a Azienda USL di Bologna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACCUPRIN; ACERTIL; ACVUTEL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CIBACE; CILAZAPRIL; CONVERSUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; FOSINOPRIL; INIBACE; INNIBACE; IRBESARTAN; LISINOPRIL; LONGES; LOSARTAN; LOSARTAN POTASSIUM; METOPROLOL; PERINDOPRIL; PREXUM; PROCAPTAN; PROPRANOLOL; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VASCACER; ZOFENOPRIL;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUDDEN DEATH;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CARDIAC PACING, ARTIFICIAL; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE, CONGESTIVE; HUMANS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS;

EID: 0036147062     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200201000-00002     Document Type: Review

References (120)

1. Heart failure. Angiotensin converting (ACE) inhibitors
2. Heart failure. Angiotensin II receptors blockers
3. Overview of randomised trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure
4. Long term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: A systematic overview of data from individual patients
5. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
6. Meta-analysis of observed mortality data from all - Controlled, double blind, multiple dose studies of losartan in heart failure
7. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with Candesartan Cilexetil
8. Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial
9. Comparison of candesartan., enalapril and their combination in congestive heart failure: Randomised evaluation of strategies for left ventricular dysfunction (RESOLVD pilot study)
10. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise in patients with severe congestive heart failure
11. Cardiac protection: Evolving role of angiotensin receptor blockers
12. Enhancing cardiac protection after myocardial infarction: Rationale for newer clinical trials of angiotensin receptors blockers
13. Effect of enalapril on morbid and mortal events among SOLVD participants with hypertension
14. Attenuation of ventricular enlargment: The SAVE study
15. A national survey of heart failure in French hospitals
16. Editorial comment: Heart failure: We need more trials in typical patients
17. Differences between patients with heart failure treated by cardiologists, internists, family physicians, and other physicians: Analysis of a large, state wide database
18. Determinats of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: The EPICAL study
19. Randomized trial of Candesartan Cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
20. Consensus recommendations for the management of chronic heart failure
21. Role of angiotensin receptors blockers in heart failure not yet RESOLVD
22. Aspetti epidemiologici generali della insufficienza cardiaca, mortalita' cardiaca generale ed improvvisa. Dai dati dei trials clinici alla epidemiologia di comunita'. In stampa
23. Significato clinico e prognostico delle aritmie sopraventricolari con particolare riferimento alla fibrillazione atriale in pazienti con insufficienza cardiaca. Approccio terapeutico moderno. In stampa
24. Aritmie ventricolari e prevenzione della morte improvvisa nella insufficienza cardiaca. Nuove prospettive terapeutiche farmacologiche e non farmacologiche
25. Clinical trials in cardiology
26. Has the survival of heart failure population changed? Lessons from trials
27. II ruolo della fibrillazione atriale parossistica e di altre aritmie nel determinismo della insufficienza ventricolare sinistra acuta in pazienti con scompenso congestizio
28. Exercise tolerance as a guide to therapeutic efficacy for heart failure. The potential for angiotensin receptors blockers
29. The primary and secondary prevention of sudden cardiac death
30. Symposium: New frontiers in the electrical management of cardiac disorders
31. Cost/Benefit of implantable defibrillator therapy
32. An update on ICD clinical trials
33. Treatment of sudden cardiac death. Current understandings from randomized trials and future research directions
34. A decade of clinical trial developments in postmyocardial infarction, congestive heart failure and sustained ventricular tachyarrhythmia patients: From CAST to AVID and beyond
35. Cost effectiveness of implantable defibrillators as first choise therapy vs electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study
36. Post AMI trials of antiarrhythmic and non antiarrhythmic drugs versus prophylactic ICD studies
37. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
38. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors
39. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargment trial SOLVD
40. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
41. A symposium: Can physicians always explain the results of clinical trials? A case study of amlodipine in heart failure
42. Arrhythmic risk stratification of post-myocardial infarction patients
43. Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery
44. Combination therapy with non anti-arrhythmic drugs in patients with congestive heart failure. Effects on total mortality and sudden cardiac death
45. Role of antiarrhythmic drugs in the prevention of sudden death and total mortality
46. Evidence-based analysis of amiodarone efficacy and safety
47. Pacing therapy for congestive heart failure: Is there a role for biventricular pacing in the new millennia?
48. Dual-chamber DDD pacing in dilated cardiomyopathy
49. Differences in the treatment of patients with ventricular arrhythmias in some European countries and USA after CAST study
50. The use of antiarrhythmic agents after the CAST study. What's next? An italian point of view
51. Which strategy is best after myocardial infarction? The beta blockers strategy plus implantable cardioverter defibrillator trial: Rational and study design
52. New primary prevention trials of sudden death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II
53. Biventricular pacing in patients with congestive heart failure: Two prospective randomized trial
54. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
55. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
56. The SWORD study. Effects of D-sotalol on moratlity in patients with left ventricular dysfunction after recent and remote myocardial infarction
57. Randomized trial effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT
58. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarization. CAMIAT
59. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and congestive heart failure: Meta-analysis of individual data from 6500 patients in randomized trials
60. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
61. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Study (CONSENSUS)
62. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
63. Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure
64. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
65. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia
66. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure
67. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
68. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
69. Mortality and morbidity in patients receiving encainide, flecainide or placebo
70. Interaction of baseline characteristics with the hazard of encainide, flecainide and moricizine therapy in patients with myocardial infarction: A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST)
71. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or miricizine in the Cardiac Arrhythmia Suppression Trial (CAST)
72. Inter-observer discordance in the classification of mechanisms of death in studies of heart failure
73. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure
74. Randomized trial of low-dose amiodarone in severe congestive heart failure
75. An update on clinical trials for the primary prevention of sudden cardiac death
76. How MUSTT respond to the objection to MADIT
77. β-adrenergic receptor blockade in chronic heart failure
78. CABG and ICD for all patients with hemodynamically significant ventricular arrhythmia and significant coronary artery disease? Do we know enough to decide-or to design a randomized trial?
79. Aritmie ventricolari in pazienti con insufficienza cardiaca. Aspetti clinici e terapeutici
80. The cardiac insufficiency bisoprolol study II (CIBIS II): Arandomised trial
81. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT HF)
82. Study to evaluate carotid ultrasound changes in patients treated with ramipril and Vitamin E
83. Incidence of sudden death during long term follow up in patients with dilated cardiomyopathy on optimal medical therapy
84. Effects of ACE inhibitor trandolapril on life expectancy of patients with reduced left ventricular function after acute myocardial infarction
85. Effect of angiotensin converting enzyme inhibition on sudden death in pateints following acute myocardial infarction: A meta analysis of randomised clinical trials
86. Betablockers, ventricular arrhythmias and sudden death in heart failure: Not as simple as it seems
87. Angiotensin II inhibition in hypertension and heart failure: Current experience and future developments
88. Regression of left ventricular hypertrophy prevents ischemia induced lethal arrhythmias: Beneficial effects of angiotensin II blockade
89. The antiarrhythmic potential of angiotensin II antagonism: Experience with Losartan
90. Azilimide post infarct survival evaluation (ALIVE) trial
91. Secondary prevention of cardiac events following myocardial infarction: Effects of atenolol and enalapril
92. Arrhythmia in patients with a cardiomyopathy and congestive heart failure. Part I
93. Effect of antithrombotic therapy on risk of sudden death in patients with congestive heart failure
94. Trandolapril in patients with postmyocardial infarction cardiac failure. The TRACE study
95. Effects of adding spironolactone to an angiotensin -converting enzyme inbitor in chronic congestive heart failure secondary to coronary artery disease. The RALES study
96. Lack of long term ventricular arrhythmias reduction by enalapril in heart failure
97. Sudden death: ACE inhibitors and betablockers
98. Update on recent clinical trials in congestive heart failure
99. Prevention of sudden cardiac death: Management considerations
100. Clinical trials
101. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction
102. Subgroup and per-protocol analysis of the randomized european trials on isolated systolic hypertension in the elderly
103. Comparison of candesartan, enalapril and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
104. The prognostic significance of a history of systemic hypertension in patients randomised to either placebo pr ramipril following acute myocardial infraction: Evidence from the AIRE study
105. Comparison of the effects of Losartan and captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL trial design
106. Experimental evidence to support ELITE
107. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril on morbidity and mortality in chronic heart failure